Dietary vitamin B intake and the risk of esophageal cancer: a meta-analysis

Jun-Li Ma 1
Yan Zhao 1
Chen-Yang Guo 1
Hong-Tao Hu 1
Lin Zheng 1
Er-Jiang Zhao 2
Hai-Liang Li 1

1Department of Radiology Intervention, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450003, China; 2Department of Epidemiology and Biostatistics, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450003, China

Background: Several epidemiology studies have explored the association between dietary B vitamins’ intake and the risk of esophageal cancer (EC). However, the results remain inconclusive. Thus, we conducted a systematic review with meta-analysis to evaluate such association.

Methods: Literature retrieval was performed using PubMed (Medline), ScienceDirect, and Cochrane Library electronic databases for all studies published from database inception to December 2017.

Results: The meta-analysis included 19 studies and showed an overall decreased risk of EC (OR = 0.77, 95% CI: 0.68–0.87) in association with multivitamin B (ie, B1, B2, B3, B5, B6, B9, and B12) dietary intake. In a subgroup analysis based on vitamin B subclass, B1, B3, B6, and B9 vitamins were associated with decreased EC risk (vitamin B1: OR = 0.68, 95% CI: 0.56–0.82; vitamin B3: OR = 0.70, 95% CI: 0.53–0.94; vitamin B6: OR = 0.64, 95% CI: 0.49–0.83; and vitamin B9: OR = 0.69, 95% CI: 0.55–0.86). By contrast, no association was detected between dietary vitamin B2 and vitamin B5 intake and EC risk (vitamin B2: OR = 0.86, 95% CI: 0.64–1.16; vitamin B5: OR = 0.49, 95% CI: 0.20–1.20), whereas a potential non-linear dose–response association was found between dietary vitamin B12 intake and EC risk. A statistically significant, inverse association was observed for an increase of 100 µg/day in supplemental vitamin B6 and B9 and EC risk (vitamin B6: OR = 0.98, 95% CI: 0.98–0.99; vitamin B9: OR = 0.89; 95% CI: 0.86–0.94).

Conclusion: These findings support that vitamin B may have an influence on carcinogenesis of the esophagus. Vitamin B1, B3, B6, B9 showed a decreased risk of EC, and vitamin B12 showed an increased risk of EC.

Keywords: B vitamins, esophageal cancer, meta-analysis

Introduction

Esophageal cancer (EC) has been ranked as the eighth most common cancer and the sixth leading cause of cancer-related deaths worldwide.1 Its epidemiology varies widely, particularly in incidence rates among geographic regions.2 The latest epidemiological studies indicated the highest rate of EC located on the “esophageal cancer belt” ie, China, South Africa, and France.3,4 Possible risk factors for EC include alcohol drinking, hot-temperature food items, cigarette smoking, chronic mucosal irritation, and a family history of cancers.5–7 Deficiency of nutrients, such as vitamins and microelements, was also found to be associated with an increased risk of EC, whereas a high intake of fruit and vegetables has been considered to be effective in prevention.4 Several previous research studies have evaluated the effect of beta-carotene, vitamin A, C, and E on EC.8–17 Regarding multivitamin B, most studies only examined folate...
intake and EC risk, and no relevant pooled analyses have been performed. Thus, we conducted a meta-analysis of the current epidemiological articles to better characterize the association between multivitamin B intake and EC risk.

**Materials and methods**

**Search strategy**

We conducted a systematic search for published articles and abstracts that evaluated the relationships between B vitamins (B1, B2, B3, B5, B6, B9, B12) and the risk of esophageal carcinoma in humans.

We conducted systematic searches of PubMed (Medline), ScienceDirect, and Cochrane Library electronic databases (from database inception to December 2017). The searches were performed using (((((cancer) OR neoplasm) OR carcinoma)) AND Esophag*) OR vitamin B1 OR vitamin B2 OR vitamin B3 OR vitamin B5 OR vitamin B6 OR vitamin B9 OR vitamin B12) OR thiamin) OR riboflavin) OR pyridoxal) OR folate) OR cyanocobalamin)) AND (((((cancer) OR neoplasm) OR carcinoma) AND Esophag*)

in all fields. In addition, we scrutinized references from relevant original reports, review articles, and meta-analyses to identify other appropriate studies.

**Inclusion criteria**

In order to be included, the following criteria were needed: 1) the study was designed as a cohort, nested case–control or case–control study; 2) the study reported vitamin B and any kind of B vitamin group intake and the risk of EC; 3) the results reported effect estimates (RR, OR) and 95% CIs for comparisons between high and low dietary vitamin B intake. When multiple levels of vitamin B intake were presented, the ratio comparing the highest intake vs the lowest intake was chosen. When data from several publications were overlapping, we selected the articles with the most comprehensive data for inclusion in this meta-analysis.

**Data extraction and quality assessment**

Two researchers independently reviewed titles and abstracts of potentially eligible research identified by the search strategy and extracted the date using a standard extraction form from each included publication: the first author’s name, publication year, source of control, study design, country where the study was performed, type of cancer, specific vitamin measured, number of cases, number of controls or cohort size, total sample size, lowest vitamin B level, highest vitamin B level, difference between the highest and lowest vitamin B levels, and the risk estimates on EC and corresponding 95% CIs for the highest vs lowest categories of vitamin B intake or for each category, factors adjusted for. Adjusted ratios were extracted in preference to non-adjusted ratios.

Two authors independently assessed the quality of included studies using the Newcastle–Ottawa Scale (NOS), which is a validated scale for assessing the quality of non-randomized studies in meta-analyses. This scale awards a maximum of 9 points to each study: 4 for selection of participants and measurement of exposure, 2 for comparability of cohorts on the basis of the design or analysis, and 3 for evaluation of methodological quality outcomes. We assigned scores of 7 or higher to high-quality studies.

**Statistical analyses**

In this meta-analysis, we calculated effect estimates (RR or OR) and 95% CIs in each study to evaluate the relationship between vitamin B intake and the risk of EC. We used a fixed effects model (Mantel–Haenszel method) when heterogeneity was negligible, and a random effects model (DerSimonian and Laird method) when heterogeneity was significant. Heterogeneity was assessed using $I^2$. Significant heterogeneity was indicated if $I^2$ values were greater than 50%. We also performed a sensitivity analysis by removing individual studies from the meta-analysis when statistically significant heterogeneity was detected. We also used Egger’s and Begg’s tests to assess publication bias. All tests were two-sided and results were regarded as statistically significant if $P<0.05$. All statistical analyses were done by using STATA software (version 12.0; StataCorp LP, College Station, TX, USA).

**Results**

**Literature search**

Figure 1 shows the literature search results and screening of this study. We identified 390 observational studies from PubMed (Medline), ScienceDirect, and Cochrane Library. A total of 332 articles were assessed after eliminating 58 duplicate papers. A total of 268 articles were excluded owing to reported irrelevant results after reviewing the title and abstract. In addition, three additional studies were found by a manual search of the reference lists. In total, full text of 67 articles was reviewed. Among them, 13 studies did not show the association of vitamin B and EC risk, because these 13 articles explored the relationship between nutrient intervention or mineral compound vitamin B or all the nutrient intake and risk of EC or precancerous lesions. Four articles did not report sufficient data for estimation of OR/RR, three articles did not separately report the 95% CI, nine articles were
reviews, 12 articles reported the prognosis of EC patients, five articles focused on gene type and vitamin B exposures, and two articles focused on blood vitamin B9, B12. As a result, 19 articles were finally selected for the meta-analysis.8,9,26–42

Characteristics and quality of included studies
We identified 19 articles in our study. Tables 1 and 2 show the main characteristics extracted from included studies. All the studies were conducted in Asia, Europe, America, and Australia and were published from 1988 to 2017. Among all the studies, one study was a cohort study42 and 18 studies were case–control studies.8,9,26–41

The quality of all studies was assessed by using the NOS scale. The overall methodological quality of articles is presented in Table 1. Overall, eleven studies had a score of 8,9,26,27,30,32,33,35,40 four had a score of 7,8,9,34,42 and the remaining studies had a score of 6,28,29,36,37,39,41.


Table 1 Characteristics of studies on B vitamin intake and esophageal cancer risk

| Author          | Year | Source of control | Study of design | Country | Cancer type | Vitamin B | Exposure ascertainment | OR (95% CI) for highest vs lowest category |
|-----------------|------|-------------------|-----------------|---------|-------------|-----------|------------------------|-------------------------------------------|
| Jessri et al    | 2011 | HB                | Case-control    | Iran    | ESCC        | VB1       | FFQ                    | 0.34 (0.06–2.85)                          |
| Ibiebele et al  | 2011 | PB                | Case-control    | Australian | EAC        | VB1       | FFQ                    | 0.78 (0.57–1.07)                          |
| Mayne et al     | 2001 | PB                | Case-control    | US      | ESCC        | VB1       | FFQ                    | 0.41 (0.25–0.67)                          |
| Zhang et al     | 1997 | HB                | Case-control    | US      | EAC         | VB1       | FFQ                    | 0.73 (0.50–1.07)                          |
| Brown et al     | 1988 | HB                | Case-control    | US      | EC          | VB1       | FFQ                    | 0.78 (0.46–1.30)                          |
| Sharp et al     | 2013 | PB                | Case-control    | Ireland | EAC         | VB2       | FFQ                    | 0.80 (0.30–2.10)                          |
| Jessri et al    | 2011 | HB                | Case-control    | Iran    | ESCC        | VB2       | FFQ                    | 0.60 (0.30–1.10)                          |
| Ibiebele et al  | 2011 | PB                | Case-control    | Australian | EAC        | VB2       | FFQ                    | 1.07 (0.63–1.82)                          |
| Mayne et al     | 2001 | PB                | Case-control    | US      | EAC         | VB2       | FFQ                    | 0.22 (0.07–0.86)                          |
| Zhao et al      | 2011 | HB                | Case-control    | Iran    | ESCC        | VB2       | FFQ                    | 1.32 (0.98–1.80)                          |
| Mayne et al     | 2001 | PB                | Case-control    | US      | ESCC        | VB3       | FFQ                    | 1.11 (0.82–1.52)                          |
| Yao et al       | 2013 | PB                | Case-control    | China    | ESCC        | VB2       | Serum                  | 1.26 (0.84–1.89)                          |
| Sani et al      | 2014 | PB                | Nested case-control | Europe | ESCC       | VB2       | Serum                  | 0.46 (0.32–0.67)                          |
| Zhang et al     | 1997 | HB                | Case-control    | US      | EAC         | VB3       | FFQ                    | 1.95 (0.84–4.52)                          |
| Chen et al      | 2009 | PB                | Case-control    | US      | EAC         | VB2       | Food records           | 0.40 (0.20–1.10)                          |
| Jessri et al    | 2011 | HB                | Case-control    | Iran    | ESCC        | VB3       | FFQ                    | 0.50 (0.20–1.00)                          |
| Ibiebele et al  | 2011 | PB                | Case-control    | Australian | EAC        | VB3       | FFQ                    | 0.38 (0.15–1.82)                          |
| Mayne et al     | 2001 | PB                | Case-control    | US      | ESCC        | VB3       | FFQ                    | 0.71 (0.52–0.96)                          |
| Zhang et al     | 1997 | HB                | Case-control    | US      | EAC         | VB3       | FFQ                    | 0.69 (0.43–1.12)                          |
| Chen et al      | 2009 | PB                | Case-control    | US      | EAC         | VB3       | FFQ                    | 1.07 (0.77–1.48)                          |
| Jessri et al    | 2011 | HB                | Case-control    | Iran    | ESCC        | VB3       | FFQ                    | 0.74 (0.48–1.16)                          |
| Sharp et al     | 2013 | PB                | Case-control    | Ireland | EAC         | VB6       | FFQ                    | 0.20 (0.10–0.70)                          |
| Jessri et al    | 2011 | HB                | Case-control    | Iran    | ESCC        | VB6       | FFQ                    | 0.80 (0.40–1.50)                          |
| Ibiebele et al  | 2011 | PB                | Case-control    | Australian | EAC        | VB3       | FFQ                    | 0.49 (0.35–2.08)                          |
| Sharp et al     | 2013 | PB                | Case-control    | Ireland | ESCC        | VB6       | FFQ                    | 0.37 (0.22–0.63)                          |
| Ibiebele et al  | 2011 | PB                | Case-control    | Australian | ESCC       | VB6       | FFQ                    | 0.17 (0.05–0.91)                          |
| Xiao et al      | 2014 | PB                | cohort          | US      | EAC         | VB6       | FFQ                    | 0.53 (0.39–0.74)                          |
| Mayne et al     | 2001 | PB                | Case-control    | US      | EAC         | VB6       | FFQ                    | 0.66 (0.42–1.05)                          |
| Fanidi et al    | 2014 | PB                | Nested Case-control | European | ESCC       | VB6       | FFQ                    | 0.86 (0.51–1.45)                          |
| Galeone et al   | 2006 | HB                | Case-control    | Italy and Swiss | EAC       | VB6       | FFQ                    | 1.00 (0.76–1.32)                          |
| Zhang et al     | 1997 | HB                | Case-control    | US      | EAC         | VB6       | FFQ                    | 0.63 (0.30–1.33)                          |
| Chen et al      | 2009 | PB                | Case-control    | US      | EAC         | VB6       | FFQ                    | 0.63 (0.30–1.33)                          |
| Ling            | 2013 | PB                | Case-control    | China    | ESCC        | VB9       | Serum                  | 0.61 (0.36–1.07)                          |
| Sharp et al     | 2013 | PB                | Case-control    | Ireland | EAC         | VB9       | FFQ                    | 0.52 (0.30–0.89)                          |
| Zhao et al      | 2011 | HB                | Case-control    | China    | ESCC        | VB9       | FFQ                    | 0.51 (0.20–1.29)                          |

Cancer Management and Research downloaded from https://www.dovepress.com/ by 207.241.231.83 on 28 April 2019
For personal use only.

For personal use only.
| Participants (cases) | Adjust variables                                                                                           | New Castle–Ottawa scale |
|---------------------|-----------------------------------------------------------------------------------------------------------|------------------------|
| 144 (48)            | Age, gender, energy intake, BMI, smoking status, physical activity, education level, gastroesophageal reflux disease symptoms | 8                     |
| 519 (147)           | Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                       | 8                     |
| 429 (57)            | Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                       | 8                     |
| 969 (282)           | Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake      | 8                     |
| 893 (206)           | Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake      | 8                     |
| 48 (18)             | NR                                                                                                        | 6                     |
| 629 (207)           | Smoking status, alcohol intake                                                                            | 6                     |
| 129 (64)            | Age, gender, total energy intake                                                                           | 9                     |
| 144 (48)            | Age, gender, energy intake, BMI, smoking status, physical activity, education level, gastroesophageal reflux disease symptoms | 8                     |
| 518 (146)           | Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                       | 8                     |
| 422 (50)            | Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                       | 8                     |
| 969 (282)           | Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake      | 8                     |
| 893 (206)           | Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake      | 8                     |
| 212 (106)           | Age, gender, site                                                                                            | 7                     |
| 252 (123)           | Age, gender, country, educational attainment, smoking status, alcohol intake                               | 8                     |
| 268 (26)            | Age, gender, country, educational attainment, smoking status, alcohol intake                               | 8                     |
| 44 (13)             | NR                                                                                                        | 6                     |
| 573 (124)           | Age, gender, respondent type, BMI, alcohol intake, tobacco use, education level, family history, vitamin supplementation use | 8                     |
| 144 (48)            | Age, gender, energy intake, BMI, smoking status, physical activity, education level, gastroesophageal reflux disease symptoms | 8                     |
| 515 (143)           | Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                       | 8                     |
| 421 (49)            | Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                       | 8                     |
| 969 (282)           | Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake      | 8                     |
| 893 (206)           | Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake      | 8                     |
| 44 (13)             | NR                                                                                                        | 6                     |
| 573 (124)           | Age, gender, respondent type, BMI, alcohol intake, tobacco use, education level, family history, vitamin supplementation use | 8                     |
| 144 (48)            | Age, gender, energy intake, BMI, smoking status, physical activity, education level, gastroesophageal reflux disease symptoms | 8                     |
| 142 (46)            | Age, gender, total energy intake                                                                           | 9                     |
| 145 (49)            | Age, gender, energy intake, BMI, smoking status, physical activity, education level, gastroesophageal reflux disease symptoms | 8                     |
| 517 (146)           | Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                       | 8                     |
| 423 (52)            | Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                       | 8                     |
| 4,471,303 (25)      | Age, gender, race, education, marital status, health status, BMI, smoking status, alcohol, vigorous physical activity, multivitamin use, family history of cancer, energy intake | 7                     |
| 4,471,303 (98)      | Age, gender, race, education, marital status, health status, BMI, smoking status, alcohol, vigorous physical activity, multivitamin use, family history of cancer, energy intake | 7                     |
| 969 (282)           | Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake      | 8                     |
| 893 (206)           | Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake      | 8                     |
| 257 (128)           | Age, gender, country, educational attainment, smoking status, alcohol intake                               | 8                     |
| 270 (16)            | Age, gender, country, educational attainment, smoking status, alcohol intake                               | 8                     |
| 405 (108)           | Age, center, education, BMI, smoking, alcohol drinking                                                    | 7                     |
| 44 (13)             | NR                                                                                                        | 6                     |
| 573 (124)           | Age, gender, respondent type, BMI, alcohol intake, tobacco use, education level, family history, vitamin supplementation use | 8                     |
| 48 (6)              | Age, gender, smoking habit, drinking                                                                      | 8                     |
| 136 (55)            | Age, gender, total energy intake                                                                           | 8                     |
| 174 (52)            | Age, gender                                                                                               | 6                     |

(Continued)
Table 1 (Continued)

| Author            | Year | Source of control | Study of design | Country          | Cancer type | Vitamin B | Exposure ascertainment | OR (95% CI) for highest vs lowest category |
|-------------------|------|-------------------|-----------------|------------------|-------------|-----------|------------------------|--------------------------------------------|
| Jessri et al      | 2011 | HB                | Case–control    | Iran             | ESCC        | VB9       | FFQ                    | 0.08 (0.02–0.90)                           |
| Chang et al       | 2015 | PB                | Case–control    | China            | EC          | VB9       | Plasma                 | 1.58 (0.95–2.64)                           |
| Ibiebele et al    | 2011 | PB                | Case–control    | Australian       | EAC         | VB9       | FFQ                    | 0.72 (0.53–0.98)                           |
| Aune et al        | 2011 | HB                | Case–control    | Uruguay          | EC          | VB9       | FFQ                    | 0.78 (0.51–1.19)                           |
| Xiao et al        | 2014 | PB                | cohort          | US               | ESCC        | VB9       | FFQ                    | 1.07 (0.59–1.94)                           |
| Mayne et al       | 2001 | PB                | Case–control    | US               | EAC         | VB9       | FFQ                    | 1.00 (0.76–1.31)                           |
| Bao et al         | 2013 | PB                | Case–control    | China            | ESCC        | VB9       | Serum                  | 0.48 (0.36–0.66)                           |
| Fanidi et al      | 2014 | PB                | Case–control    | European         | ESCC        | VB9       | Serum                  | 0.58 (0.39–0.86)                           |
| Galeone et al     | 2006 | HB                | Case–control    | Italy and Swiss  | EAC         | VB9       | Serum                  | 0.43 (0.29–0.62)                           |
| Tavani et al      | 2012 | HB                | Case–control    | Italy            | EC          | VB9       | FFQ                    | 1.03 (0.47–2.24)                           |
| Bollschweil et al | 2002 | PB                | Case–control    | Germany          | EAC         | VB9       | FFQ                    | 1.68 (0.79–3.56)                           |
| Zhang et al       | 1997 | HB                | Case–control    | US               | EAC         | VB9       | FFQ                    | 0.68 (0.46–1.00)                           |
| Qin et al         | 2008 | HB and PB        | Case–control    | China            | EC          | VB9       | FFQ                    | 0.26 (0.14–0.48)                           |
| Brown et al       | 1998 | HB                | Case–control    | US               | EC          | VB9       | FFQ                    | 0.50 (0.30–1.00)                           |
| Chen et al        | 2009 | PB                | Case–control    | US               | EAC         | VB9       | HHHQ                   | 3.20 (1.30–9.10)                           |
| Yang et al        | 2005 | HB                | Case–control    | Japan            | EC          | VB9       | SQFFQ                  | 0.70 (0.30–1.70)                           |
| Sharp et al       | 2013 | PB                | Case–control    | Ireland          | EAC         | VB12      | FFQ                    | 0.52 (0.33–0.82)                           |
| Jessri et al      | 2011 | HB                | Case–control    | Iran             | ESCC        | VB12      | FFQ                    | 0.70 (0.40–1.30)                           |
| Chang et al       | 2015 | PB                | Case–control    | China            | EC          | VB12      | Plasma                 | 0.72 (0.575–95% CI: 0.575–95% CI: 0.59–0.83). There was statistically significant heterogeneity among all the studies (I²=77.9%; P=0.00).

**Multivitamin B intake**

Our results showed a statistically significant inverse association between use of multivitamin B supplements and EC (OR=0.70; 95% CI: 0.59–0.83). There was statistically significant heterogeneity among all the studies (I²=77.9%; P=0.00).

**Subgroup analysis of the source of the control group**

Subgroup analysis of the source of the control group showed that dietary vitamin B was a protective factor for EC in both subgroups (hospital-based: OR=0.575, 95% CI: 0.492–0.672; population-based: OR=0.868, 95% CI: 0.820–0.919).
Dietary vitamin B intake and the risk of EC: a meta-analysis

Subgroup analysis of EC pathological types
Subgroup analysis based on EC pathological types showed that dietary vitamin B was protective against esophageal squamous cell carcinoma (OR=0.762, 95% CI: 0.697–0.833) and esophageal adenocarcinoma (OR=0.870, 95% CI: 0.811–0.933).

Vitamin B1 intake
The association between vitamin B1 intake and EC risk was examined in seven case-control studies. The multivariable adjusted ORs for each study and combination of all studies for the highest vs lowest level of dietary vitamin B1 intake are shown in Figure 2. The pooled OR of EC for the highest
Table 2 Characteristics of studies on B vitamin intake

| Author          | Year | Vitamin B | Exposure ascertainment | Highest vs lowest category |
|-----------------|------|-----------|------------------------|---------------------------|
| Jessri et al    | 2011 | VB1       | FFQ                    | –                         |
| Ibiebele et al  | 2011 | VB1       | FFQ                    | 0.4–1.5 vs 2.1–5.8 (mg/d) |
| Mayne et al     | 2001 | VB1       | FFQ                    | –                         |
| Zhang et al     | 1997 | VB1       | FFQ                    | –                         |
| Brown et al     | 1988 | VB1       | FFQ                    | –                         |
| Sharp et al     | 2013 | VB2       | FFQ                    | ≤1.8 vs ≥2.8 mg (mg/d)    |
| Jessri et al    | 2011 | VB2       | FFQ                    | –                         |
| Ibiebele et al  | 2011 | VB2       | FFQ                    | 0.5–1.8 vs 2.7–7.1 (mg/d) |
| Mayne et al     | 2001 | VB2       | FFQ                    | –                         |
| Bao et al       | 2013 | VB2       | Serum                  | <2,401.86 vs >2845.42 (μg/L) |
| Fanidi et al    | 2014 | VB2       | Serum                  | 2.5–9.4 vs 21.4–199 (nmol/L) |
| Zhang et al     | 1997 | VB2       | Food records           | –                         |
| Chen et al      | 2009 | VB2       | Validated HHHQ         | –                         |
| Jessri et al    | 2011 | VB3       | FFQ                    | –                         |
| Ibiebele et al  | 2011 | VB3       | FFQ                    | 28–50 mg                  |
| Mayne et al     | 2001 | VB3       | FFQ                    | –                         |
| Zhang et al     | 1997 | VB3       | FFQ                    | –                         |
| Chen et al      | 2009 | VB3       | Validated HHHQ         | –                         |
| Jessri et al    | 2011 | VB5       | FFQ                    | –                         |
| Sharp et al     | 2013 | VB6       | FFQ                    | ≤2.3 vs ≥3.2 (mg/d)       |
| Jessri et al    | 2011 | VB6       | FFQ                    | –                         |
| Ibiebele et al  | 2011 | VB6       | FFQ                    | 0.3–1.1 vs 1.5–3.0 (mg/d) |
| Xiao et al      | 2014 | VB6       | FFQ                    | 0.3–1.1 vs 1.5–3.0 (mg/d) |
| Mayne et al     | 2001 | VB6       | FFQ                    | –                         |
| Fanidi et al    | 2014 | VB6       | Serum                  | 7.2–25.6 vs 47.7–272 (nmol/L) |
| Galeone et al   | 2006 | VB6       | FFQ                    | –                         |
| Zhang et al     | 1997 | VB6       | FFQ                    | –                         |
| Chen et al      | 2009 | VB6       | Validated HHHQ         | –                         |
| Ling et al      | 2013 | VB9       | Serum                  | <17.04 vs >34.19 (μg/L)   |
| Sharp et al     | 2013 | VB9       | FFQ                    | ≤318 vs ≥421 (μg/d)       |
| Zhao et al      | 2011 | VB9       | FFQ                    | <230 vs >300 (μg/d)       |
| Jessri et al    | 2011 | VB9       | FFQ                    | –                         |
| Chang et al     | 2015 | VB9       | Plasma                 | ≤8.90 vs ≥17.66 (nmol/L)  |
| Ibiebele et al  | 2011 | VB9       | FFQ                    | 42–230 vs 336–673 (μg/d)  |
| Aune et al      | 2011 | VB9       | FFQ                    | –                         |
| Xiao et al      | 2014 | VB9       | FFQ                    | –                         |
| Mayne et al     | 2001 | VB9       | FFQ                    | –                         |
| Bao et al       | 2013 | VB9       | Serum                  | <28.27 vs >35.06 (μg/L)   |
| Fanidi et al    | 2014 | VB9       | Serum                  | 0.3–9.1 to -18.2–109 (nmol/L) |
| Galeone et al   | 2006 | VB9       | FFQ                    | –                         |
| Tavani et al    | 2012 | VB9       | FFQ                    | <208.77 vs >312.47 (μg/d) |

(Continued)
Dietary vitamin B intake and the risk of eC: a meta-analysis

Table 2 (Continued)

| Author            | Year | Vitamin B Exposure ascertainment | Highest vs lowest category |
|-------------------|------|----------------------------------|---------------------------|
| Bollschweiler et al | 2002 | VB9 FFQ                          | 0–164 (μg/d)              |
| Zhang et al       | 1997 | VB9 FFQ                          | 0–164 (μg/d)              |
| Qin et al         | 2008 | VB9 FFQ                          | --                        |
| Brown et al       | 1988 | VB9 FFQ                          | --                        |
| Chen et al        | 2009 | VB9 HHHQ                         | --                        |
| Yang et al        | 2005 | VB9 SQFFQ                        | <300 vs >400 (μg/d)       |
| Sharp et al       | 2013 | VB12 FFQ                         | ≤6.4 vs ≥9.7 (μg/d)       |
| Jessri et al      | 2011 | VB12 FFQ                         | --                        |
| Chang et al       | 2015 | VB12 Plasma                      | ≤154.23 vs >324.06 (pmol/L) |
| Ibiebele et al    | 2011 | VB12 FFQ                         | 0–1.1 vs 2.1–7.8 (μg/d)   |
| Xiao et al        | 2014 | VB12 FFQ                         | 0–1.1 vs 2.1–7.8 (μg/d)   |
| Mayne et al       | 2001 | VB12 FFQ                         | --                        |
| Fanidi et al      | 2014 | VB12 Serum                       | 75.1–265 vs 392–2,737 (pmol/L) |
|                   |      | VB12 Serum                       | 75.1–265 vs 392–2,737 (pmol/L) |

Abbreviations: VB, vitamin B; FFQ, food frequency questionnaires; HHHQ, health habits and history questionnaires; SQFFQ, semi-quantitative food frequency questionnaires.

Figure 2 Forest plot between highest vs lowest categories of vitamin B1 intake and EC risk. 
Abbreviation: EC, esophageal cancer.

vs lowest level of vitamin B1 intake was 0.68 (95% CI: 0.56–0.82). No heterogeneity was detected (I²=0%, P=0.432). It was not possible to perform dose–response meta-analyses due to limited data.

Vitamin B2 intake

We did not observe a statistically significant association for vitamin B2 supplements and EC risk (Figure 3, OR=0.86; 95% CI: 0.64–1.16) based on eleven studies. There was
statistically significant heterogeneity among the studies on dietary vitamin B2 intake ($I^2=70.2\%; P<0.001$).

**Vitamin B3 intake**

As shown in Figure 4, seven studies examined the association between vitamin B3 intake and EC risk. The pooled OR for the highest vs lowest vitamin B3 intake was 0.70 (95% CI: 0.53–0.94, $I^2=53.9\%; P=0.043$). Dose–response meta-analyses were not done due to data limitations.

**Vitamin B5 intake**

There was only one study which showed the association between vitamin B5 intake and EC risk (OR=0.49, 95% CI:0.20–1.20), suggesting that vitamin B5 intake was not significantly associated with the risk of EC.

**Vitamin B6 intake**

A total of 13 studies assessed the association between dietary vitamin B6 intake and EC risk. Figure 5 shows that the pooled OR of EC risk for the highest vs lowest categories of vitamin B6 intake was 0.64 (95% CI: 0.49–0.83, $I^2=73.0\%; P=0.00$), indicating that vitamin B6 intake had a protective effect against EC risk. For an increase of 100 µg/day of dietary vitamin B6 intake, a statistically significant, inverse association with EC risk (OR=0.98, 95% CI: 0.98–0.99) was detected.

**Vitamin B9 intake**

The association between dietary folate intake and EC risk was examined in 15 studies. The multivariable adjusted ORs for each study and combination of all studies for the highest vs lowest level of dietary folate intake are shown in Figure 6. The pooled OR of EC for the highest vs lowest level of dietary folate intake was 0.63 (95% CI: 0.56–0.71). There was statistically significant heterogeneity among the studies on dietary folate intake ($I^2=70.2\%; P=0.00$). Dose–response meta-analysis was based on seven studies. A statistically significant, inverse association was observed for an increase of 100 µg/day in supplemental vitamin B9 and EC risk (OR=0.89; 95% CI: 0.86–0.94).

**Vitamin B12 intake**

Inconsistent associations were observed for use of vitamin B12 supplements and EC risk in our study (OR=1.34, 95%
**Figure 4** Forest plot between highest vs lowest categories of vitamin B3 intake and esophageal cancer risk. 
*Abbreviation: ES.*

**Table 1**

| Study ID      | ES (95% CI)   | Weight |
|---------------|---------------|--------|
| Zhang (1997)  | 0.20 (0.10–0.70) | 6.66   |
| Mayne (2001)  | 1.07 (0.77–1.48) | 21.51  |
| Mayne (2001)  | 0.74 (0.48–1.16) | 17.44  |
| Chen (2009)   | 0.80 (0.40–1.50) | 11.47  |
| Jessri (2011) | 0.38 (0.15–1.82) | 4.44   |
| Ibiebele (2011)| 0.71 (0.52–0.96) | 22.26  |
| Ibiebele (2011)| 0.69 (0.43–1.12) | 16.23  |
| Overall (I²=53.9%, P=0.043) | 0.70 (0.53–0.94) | 100.00 |

*Note: weights are from random effects analysis.*

**Figure 5** Forest plot between highest vs lowest categories of vitamin B6 intake and esophageal cancer risk. 
*Abbreviation: ES.*

**Table 2**

| Study ID      | ES (95% CI)   | Weight |
|---------------|---------------|--------|
| Zhang (1997)  | 0.20 (0.10–0.70) | 4.55   |
| Mayne (2001)  | 0.53 (0.38–0.73) | 10.10  |
| Mayne (2001)  | 0.45 (0.30–0.69) | 9.21   |
| Galeone (2006)| 0.99 (0.60–1.31) | 9.47   |
| Chen (2009)   | 0.70 (0.30–1.30) | 6.21   |
| Jessri (2011) | 0.17 (0.05–0.91) | 2.59   |
| Ibiebele (2011)| 0.53 (0.39–0.74) | 10.16  |
| Ibiebele (2011)| 0.66 (0.42–1.05) | 8.78   |
| Sharp (2013)  | 0.37 (0.22–0.63) | 8.10   |
| Xiao (2014)   | 0.86 (0.51–1.45) | 8.14   |
| Xiao (2014)   | 1.00 (0.76–1.32) | 10.57  |
| Fanidi (2014) | 2.26 (1.06–4.84) | 6.00   |
| Fanidi (2014) | 0.63 (0.30–1.33) | 6.12   |
| Overall (I²=73.0%, P=0.000) | 0.64 (0.49–0.83) | 100.00 |

*Note: weights are from random effects analysis.*
CI: 1.05–1.70). Heterogeneity was high ($I^2 = 73.6\%$, $P = 0.00$), as shown in Figure 7. Using restricted cubic spline function, we found a potential non-linear dose–response association between dietary vitamin B12 intake and EC risk ($P_{\text{non-linearity}} = 0.0001$) (Figure 8). The non-linear curve showed that there was a dose–response association between vitamin B12 dose and decreased risk of EC approximately below 5.5 µg/day, whereas the EC risk did not decrease further above 5.5 µg/day.

**Publication bias**

Publication bias was evaluated by Egger’s and Begg’s tests. The results disclosed no evidence of publication bias for EC (Egger: $t = 0.38, P = 0.575$; Begg: $z = 1.34, P = 0.179$).

**Sensitivity analysis**

As a result, a sensitivity analysis of multivitamin B intake was conducted, and after each study was sequentially excluded from the pooled analysis, the conclusion was not affected by exclusion of any specific study.

**Discussion**

Epidemiological investigations have suggested that there are significant relationships between diet-associated factors and EC. B vitamins may be one factor. Because some B vitamins cannot be synthesized in the human body, they can only be obtained through dietary. Fruit and vegetables are important dietary sources of some B vitamins. The reason why vitamin
Dietary vitamin B intake and the risk of EC: a meta-analysis

B affects the risk of cancer may be because it is essential for the biosynthesis of nucleotides, replication of DNA, supply of methyl groups, and the growth and repair of cells.43–46

In the present review, there was no epidemiologic research that assessed the association between total B vitamin consumption and EC risk among people. There were only studies which evaluated the relationship between several subclasses of B vitamins and EC risk. Thus, this study is the most comprehensive meta-analysis providing evidence to indicate these results. We found that total vitamin B intake was significantly associated with reduced EC risk. In addition, we evaluated the potential association of vitamin B subclasses and EC risk, respectively. In the subgroup analysis, we found that vitamin B1, B3, B6, and B9 may be protective factors, but vitamin B12, in contrast, was positively associated with risk of EC.

Previous studies have shown that consuming large quantities of vegetables, fruit, vitamins, and antioxidants can reduce the risk of EC.47–49 One potential reason for vitamin B12 being different from other B vitamins may be because it is derived exclusively from foods of animal origin, and it is simply a marker for consumption of animal protein. In previous studies, the risk of adenocarcinomas of the esophagus was linked to high-fat diets50,51 because esophageal adenocarcinoma generally arises from Barrett’s epithelium.52 Additionally, research has shown that diets low in animal protein and rich in fruit, vegetables, and fiber can reduce the risk of malignant transformation.33,47

| Study ID          | ES (95% CI)          | % weight |
|-------------------|----------------------|----------|
| Mayne (2001)      | 1.39 (1.10–1.76)     | 12.36    |
| Mayne (2001)      | 1.51 (1.15–2.00)     | 11.83    |
| Jessri (2011)     | 1.33 (0.60–3.03)     | 5.45     |
| Ibiebele (2011)   | 0.96 (0.71–1.30)     | 11.48    |
| Ibiebele (2011)   | 0.89 (0.58–1.32)     | 9.96     |
| Sharp (2013)      | 3.87 (2.22–6.73)     | 8.06     |
| Xiao (2014)       | 0.85 (0.52–1.41)     | 8.77     |
| Xiao (2014)       | 1.04 (0.80–1.34)     | 12.08    |
| Fanidi (2014)     | 1.07 (0.51–2.23)     | 6.08     |
| Fanidi (2014)     | 1.17 (0.56–2.44)     | 6.09     |
| Chang (2015)      | 3.07 (1.73–5.45)     | 7.83     |
| Overall (I²=73.6%, P=0.000) | 1.34 (1.05–1.70) | 100.00  |

Note: weights are from random effects analysis

Figure 7 Forest plot between highest vs lowest categories of vitamin B12 intake and esophageal cancer risk.

Abbreviation: ES.

Figure 8 Non-linear dose–response analysis on vitamin B12 intake and esophageal cancer risk.
B-group vitamin supplementation may have antioxidant and anti-inflammatory effects.\textsuperscript{53,54} The biological mechanisms responsible for the protective effect of high-dosage vitamin B are unclear. One possible explanation is that B vitamins and additional nutrients sourced from fruit and vegetables are involved in the one-carbon metabolism.\textsuperscript{55–57} The metabolic pathway of one-carbon metabolism has been frequently implicated in carcinogenesis, because of its involvement in maintaining nucleotide biosynthesis and methylation reactions. Imbalances and deficiencies among crucial one-carbon metabolism nutrients may interfere with DNA replication, DNA repair, and regulation of gene expression, any of which could promote carcinogenesis.\textsuperscript{58,59} Like the vitamin B3, vitamin B6 and vitamin B9, they are indispensable in the biosynthesis of four bases of DNA (thymidine, guanine, adenine, and cytosine). Deficiency of one or more of the three vitamins required for DNA maintenance is known to cause abnormal pairing of the four bases, which can then result in mutations and the development of cancer.\textsuperscript{60} Intake of vitamin B6 was reported to increase immunoglobulin G and T4(helper) lymphocytes in humans.\textsuperscript{61} Folate deficiency was suggested to be related to increased carcinogenesis, an effect that may be mediated through participation in methyl metabolism.\textsuperscript{62}

**Limitations**

There were some limitations in our study that should be addressed. First, most studies included in our analysis were case–control studies, which may have caused recall bias, and could have caused potential heterogeneity, although the methodological quality of these observational studies was medium to high. More prospective cohort studies are needed to test this association. Second, it was a challenge to evaluate the quantity of vitamin B intake accurately because vitamin B can be sourced from various food types, and may be influenced by the type of cultivation, crop variety and location, as well as the specific morphological part of the plant eaten.

In conclusion, results from the present meta-analysis indicate that vitamin B intake is inversely associated with EC risk.

**Conclusion**

Our findings support that vitamin B may have an influence on carcinogenesis of the esophagus. Vitamin B1, B3, B6, and B9 showed a decreased risk of EC, vitamin B12 showed an increased risk of EC. (It is clear that scientists must apply the very best science in characterizing the safety of vitamin supplements.)

**Acknowledgment**

This work was funded by the MiaoPu Foundation of Henan Cancer Hospital.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359–E386.
2. Di Pardo BJ, Bronson NW, Diggs BS, Thomas CR Jr, Hunter JG, Dolan JP. The Global Burden of Esophageal Cancer: A Disability-Adjusted Life-Year Approach. *World J Surg*. 2016;40(2):395–401.
3. Boyle P, Levin B. World cancer report Lyon, France: IARC Press. 2008.
4. Muñoz N. Epidemiological aspects of oesophageal cancer. *Endoscopy*. 1993;25(9):609–612.
5. Wang JM, Xu B, Rao JY, Shen HB, Xue HC, Jiang QW. Diet habits, alcohol drinking, tobacco smoking, green tea drinking, and the risk of esophageal squamous cell carcinoma in the Chinese population. *Eur J Gastroenterol Hepatol*. 2007;19(2):171–176.
6. Morita M, Kumashiro R, Kubo N, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. *Int J Clin Oncol*. 2010;15(2):126–134.
7. Falk GW. Risk factors for esophageal cancer development. *Surg Oncol Clin N Am*. 2009;18(3):469–485.
8. Galeone C, Pelucchi C, Levi F, et al. Folate intake and squamous-cell carcinoma of the oesophagus in Italian and Swiss men. *Ann Oncol*. 2006;17(3):521–525.
9. Aune D, Deneo-Pellegrini H, Ronco AL, et al. Dietary folate intake and the risk of 11 types of cancer: a case-control study in Uruguay. *Ann Oncol*. 2011;22(2):444–451.
10. World Cancer Research Fund/American Institute for Cancer Research. *Food, nutrition, physical activity and the prevention of cancer: A global perspective*. Washington, DC: AICR; 2007.
11. Sanjoaquin MA, Allen N, Couto E, Roddam AW, Key TJ. Folate intake and colorectal cancer risk: A meta-analytical approach. *Int J Cancer*. 2005;113(5):825–828.
12. Larsson SC, Giovannucci E, Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. *Gastroenterology*. 2006;131(4):1271–1283.
13. Chainani-Wu N. Diet and oral, pharyngeal, and esophageal cancer. *Nutr Cancer*. 2002;44(2):104–126.
14. Terry P, Lagergren J, Ye W, Nyrén O, Wolk A. Antioxidants and cancers of the esophagus and gastric cardia. *Int J Cancer*. 2000;87(5):750–754.
15. Tuyns AJ, Riboli E, Doornbos G, Péquignot G. Diet and esophageal cancer in Calvados (France). *Int J Cancer*. 2000;87(5):750–754.
16. Decarli A, Liati P, Negri E, Franceschi S, La Vecchia C. Vitamin A and other dietary factors in the etiology of esophageal cancer. *Nutr Cancer*. 1987;10(1-2):29–37.
17. Nomura AM, Ziegler RG, Stemmermann GN, Chyou PH, Craft NE. Alcohol drinking, cigarette smoking, and the risk of 11 types of cancer: a case-control study in Kentucky. *Ann Oncol*. 2006;11(5):E359–E386.
18. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. *Ottawa (ON): Ottawa Hospital Research Institute; 2009. Available from: http://www.ohri.ca/programs/. Accessed September 12, 2018.
19. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0; 2011. Available from: https://training.cochrane.org/handbook. Accessed September 12, 2018.
Dietary vitamin B intake and the risk of EC: a meta-analysis

20. Chak E, Rutherford GW, Steinmaus C. The role of breast-feeding in the prevention of Helicobacter pylori infection: a systematic review. *Clin Infect Dis.* 2009;48(4):430–437.

21. Li Y, Yang H, Cao J. Association between Alcohol Consumption and Cancers in the Chinese Population—A Systematic Review and Meta-Analysis. *PLoS One.* 2011;6(4):e18776.

22. Deeks JJ, Higgins JPT, Altman DG. Analyzing data and undertaking meta-analyses, Ch. 9. In: Higgins J, Oxford Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions 3.0.1.* UK: The Cochrane Collaboration; 2008.

23. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003;327(7414):557–560.

24. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ.* 1997;315(7109):629–634.

25. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics.* 1994;50(4):1088–1101.

26. Bollschweiler E, Wolfgarten E, Nowroth T, Rosendahl U, Mönig S, Hölscher A. Vitamin intake and risk of subtypes of esophageal cancer in Germany. *J Cancer Res Clin Oncol.* 2002;128(10):575–580.

27. Huang GL, Wang SK, Su M, et al. Serum folate, MTHFR C677T Polymorphism and Esophageal Squamous Cell Carcinoma Risk. *Biomed Environ Sci.* 2013;26(12):1008–1012.

28. Sharp L, Casis AE, Cantwell MM, Anderson LA, Murray LJ; FINBAR Study Group. Intakes of Dietary Folate and Other B Vitamins are Associated with Risks of Esophageal Adenocarcinoma, Barrett’s Esophagus, and Reflux Esophagitis. *Natr J.* 2013;143(12):1966–1973.

29. Zhao P, Lin F, Li Z, Lin B, Lin J, Luo R. Folate intake, methylenetetrahydrofolate reductase polymorphisms, and risk of esophageal cancer. *Asian Pac J Cancer Prev.* 2011;12(8):2019–2023.

30. Jessri M, Rashidkhani B, Hajizadeh B, Jessri M, Gotay C. Macronutrient, vitamins and minerals intake and risk of esophageal squamous cell carcinoma: a case-control study in Iran. *Nutr J.* 2011;20:10–137.

31. Chang S-C, Goldstein BY, Mu L, et al. Plasma folate, vitamin B12, and homocysteine and cancers of the esophagus, stomach, and liver in a Chinese population. *Nutr Cancer.* 2015;67(2):212–223.

32. Ibieberle TI, Hughes MC, Pandeya N, et al. Study of Digestive Health; 2001;13(6):915–927.

33. Mayne ST, Risch HA, Dubrow R, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancers: classification tree analysis. *Ann Epidemiol.* 2014;24(1):50–57.

34. Brown LM, Swanson CA, Gridley G, et al. Adenocarcinoma of the Esophagus: Role of Obesity and Diet. *J Natl Cancer Inst.* 1995;87(2):104–109.

35. Pali D, Bianchi S, Decarlì A, et al. A case-control study of cancers of the gastric cardia in Italy. *Br J Cancer.* 1992;65(2):263–266.

36. Kabat GC, Ng SK, Wynder EL. Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. *Cancer Causes Control.* 1993;4(2):123–132.

37. Tzonou A, Lipworth L, Garioud A, et al. Diet and risk of esophageal cancer by histologic type in a low-risk population. *Int J Cancer.* 1996;68(3):304–300.

38. Kim R, Weissfeld JL, Reynolds JC, Kuller LH. Etiology of Barrett’s metaplasia and esophageal adenocarcinoma. *Cancer Epidemiol Biomark Prev.* 1997;6(5):369–377.

39. Ullegaddi R, Powers HJ, Gariballa SE. B-group vitamin supplementation mitigates oxidative damage after acute ischemic stroke. *Biochem Biophys Res Commun.* 2004;310(5):477–484.

40. Ullegaddi R, Powers HJ, Gariballa SE. Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: a randomized controlled trial. *JPN J Parenter Enteral Nutr.* 2006;30(2):108–114.

41. Olsen A, Halkjær J, van Gils CH, et al. Dietary intake of the water-soluble vitamins B1, B2, B6, B12 and C in 10 countries in the European Prospective Investigation into Cancer and Nutrition. *Eur J Clin Nutr.* 2009;63(Suppl 4):S122–S149.

42. United States Department of Health and Human Services USDAA. *Dietary Guidelines for Americans, U.S. Dept of Health and Human Services 2005.* Washington DC: US Dept of Agriculture; 2005.

43. WCRF/AICR. Food, nutrition, physical activity and the prevention of cancer. A global perspective. USA: World Cancer Research Fund International; 2007.

44. Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. *J Nutr.* 2000;130(2):129–132.

45. Kim Y. Folate and carcinogenesis: evidence, mechanisms, and implications. *J Nutr Biochem.* 1999;10(2):66–88.

46. Folkers K. Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy, *Biochem Biophys Res Commun.* 1996;224(2):358–361.

47. Folkers K, Morita M, McRee J Jr. The Activities of Coenzyme Q10 and Vitamin B6 for Immune Responses. *Biochem Biophys Res Commun.* 1993;193(1):88–92.

48. Rogers AE. Methyl donors in the diet and responses to chemical carcinogens. *Am J Clin Nutr.* 1995;61(3 Suppl):659–665S.
